SG10201901057UA - Anti-pd-l1 antibodies - Google Patents

Anti-pd-l1 antibodies

Info

Publication number
SG10201901057UA
SG10201901057UA SG10201901057UA SG10201901057UA SG10201901057UA SG 10201901057U A SG10201901057U A SG 10201901057UA SG 10201901057U A SG10201901057U A SG 10201901057UA SG 10201901057U A SG10201901057U A SG 10201901057UA SG 10201901057U A SG10201901057U A SG 10201901057UA
Authority
SG
Singapore
Prior art keywords
antibodies
antigen
methods
binding fragments
present
Prior art date
Application number
SG10201901057UA
Other languages
English (en)
Inventor
Jiping Zha
Ziyong Sun
Junzhuan Qiu
Original Assignee
Cb Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cb Therapeutics Inc filed Critical Cb Therapeutics Inc
Publication of SG10201901057UA publication Critical patent/SG10201901057UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG10201901057UA 2014-08-05 2015-08-05 Anti-pd-l1 antibodies SG10201901057UA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2014083715 2014-08-05

Publications (1)

Publication Number Publication Date
SG10201901057UA true SG10201901057UA (en) 2019-03-28

Family

ID=55264464

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201700687TA SG11201700687TA (en) 2014-08-05 2015-08-05 Anti-pd-l1 antibodies
SG10201901057UA SG10201901057UA (en) 2014-08-05 2015-08-05 Anti-pd-l1 antibodies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201700687TA SG11201700687TA (en) 2014-08-05 2015-08-05 Anti-pd-l1 antibodies

Country Status (14)

Country Link
US (3) US10435470B2 (fr)
EP (1) EP3177649B1 (fr)
JP (2) JP6909153B2 (fr)
KR (1) KR102476226B1 (fr)
CN (3) CN110964108B (fr)
AU (2) AU2015301126B2 (fr)
CA (1) CA2956399A1 (fr)
IL (1) IL250415B (fr)
MX (2) MX2017001597A (fr)
NZ (2) NZ728749A (fr)
RU (1) RU2722212C9 (fr)
SG (2) SG11201700687TA (fr)
WO (1) WO2016022630A1 (fr)
ZA (1) ZA201700785B (fr)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4169951A1 (fr) 2008-12-09 2023-04-26 F. Hoffmann-La Roche AG Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
SG10201900571YA (en) 2014-07-22 2019-02-27 Cb Therapeutics Inc Anti-pd-1 antibodies
CA2956399A1 (fr) 2014-08-05 2016-02-11 Cb Therapeutics, Inc. Anticorps anti-pd-l1
CA2978942A1 (fr) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procedes d'utilisation
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
SI3456346T1 (sl) 2015-07-30 2021-11-30 Macrogenics, Inc. Molekule za vezavo PD-1 in LAG-3 in postopki za uporabo le-teh
CA3003969A1 (fr) 2015-11-06 2017-05-11 Orionis Biosciences Nv Proteines chimeres bifonctionnelles et leurs utilisations
GEP20217328B (en) 2015-12-14 2021-12-10 Macrogenics Inc Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
EP3411407B1 (fr) 2016-02-05 2024-04-03 Orionis Biosciences BV Agent de signalisation bispécifique
KR102343742B1 (ko) * 2016-05-09 2021-12-24 아이쥐엠 바이오사이언스 인코포레이티드 항-pd-l1 항체
US11753463B2 (en) 2016-05-13 2023-09-12 Orionis Biosciences BV Therapeutic targeting of non-cellular structures
WO2017194783A1 (fr) 2016-05-13 2017-11-16 Orionis Biosciences Nv Interféron bêta mutant ciblé, et utilisations associées
CN105968200B (zh) * 2016-05-20 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-l1人源化单克隆抗体及其应用
CN106008714B (zh) 2016-05-24 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-1人源化单克隆抗体及其应用
CN107460221B (zh) * 2016-06-02 2021-01-15 正大天晴药业集团股份有限公司 一种降低抗pd-l1抗体中蛋白聚合物的细胞培养方法
WO2017218435A1 (fr) * 2016-06-13 2017-12-21 Askgene Pharma Inc. Anticorps monoclonaux spécifiques de pd-l1 pour le traitement et le diagnostic de maladies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018029474A2 (fr) 2016-08-09 2018-02-15 Kymab Limited Anticorps anti-icos
AU2017281830B2 (en) 2016-06-20 2023-04-06 Kymab Limited Anti-PD-L1 antibodies
EP3497129A1 (fr) 2016-08-08 2019-06-19 H. Hoffnabb-La Roche Ag Méthodes thérapeutiques et de diagnostic du cancer
RU2764548C2 (ru) 2016-08-09 2022-01-18 Кимаб Лимитед Анти-icos антитела
DK3507373T3 (da) 2016-08-31 2023-10-30 Biocytogen Pharmaceuticals Beijing Co Ltd Genetisk modificeret ikke-menneskeligt dyr med human eller kimær pd-l1
CN107815466B (zh) 2016-08-31 2020-03-13 百奥赛图江苏基因生物技术有限公司 人源化基因改造动物模型的制备方法及应用
US11084859B2 (en) 2016-10-24 2021-08-10 Orionis Biosciences BV Targeted mutant interferon-gamma and uses thereof
WO2018083248A1 (fr) 2016-11-03 2018-05-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
CN108203720A (zh) * 2016-12-20 2018-06-26 上海生博生物医药科技有限公司 能靶向Her2并封闭PD-L1降低肿瘤免疫逃逸的CAR-T载体及其构建方法和应用
EP3576765A4 (fr) 2017-02-06 2020-12-02 Orionis Biosciences, Inc. Interféron d'ingénierie ciblé et utilisations de ce dernier
JP7476467B2 (ja) 2017-02-06 2024-05-01 オリオンズ バイオサイエンス ビーブイ 標的化キメラタンパク質及びその使用
CN108456251A (zh) * 2017-02-21 2018-08-28 上海君实生物医药科技股份有限公司 抗pd-l1抗体及其应用
RU2665790C1 (ru) 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1
CN107299110B (zh) * 2017-05-27 2019-11-22 上海优卡迪生物医药科技有限公司 一种基于octs技术的胰腺癌、恶性间皮瘤car-t治疗载体及其构建方法和应用
CN107267555B (zh) * 2017-05-27 2020-03-20 上海优卡迪生物医药科技有限公司 一种基于octs技术的恶性胶质瘤car-t治疗载体及其构建方法和应用
CN107164410B (zh) * 2017-05-27 2019-09-03 上海优卡迪生物医药科技有限公司 一种基于octs技术的前列腺癌car-t治疗载体及其构建方法和应用
EP3630838A1 (fr) 2017-06-01 2020-04-08 CytomX Therapeutics, Inc. Anticorps anti-pdl1 activables, et leurs procédés d'utilisation
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
US20200237906A1 (en) * 2017-11-02 2020-07-30 Nanjing Shunxin Pharmaceutical Co., Ltd. Pharmaceutical Composition of Humanized Monoclonal Anti-PD-L1 Antibody
US11629189B2 (en) 2017-12-19 2023-04-18 Kymab Limited Bispecific antibody for ICOS and PD-L1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
KR102311838B1 (ko) * 2017-12-27 2021-10-14 주식회사 파멥신 항-pd-l1 항체 및 이의 용도
CN115925943A (zh) * 2017-12-27 2023-04-07 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
CA3078849A1 (fr) * 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Anticorps et leurs variants diriges contre pd-l1
AU2019206958A1 (en) * 2018-01-10 2020-07-16 Jiangsu Hengrui Medicine Co., Ltd. PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
AU2019215440A1 (en) 2018-02-05 2020-08-27 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
CN112424222A (zh) * 2018-02-17 2021-02-26 冠科美博有限公司 使用中性粒细胞调节剂与免疫检查点调节剂的组合的癌症治疗
CA3094534A1 (fr) * 2018-03-19 2019-09-26 Abeome Corporation Anticorps monoclonaux neutralisants a haute affinite envers un ligand de mort programmee 1 (pd-l1) et leurs utilisations
CN113087799B (zh) * 2018-04-09 2023-03-31 原启生物科技(上海)有限责任公司 抗pd-l1抗体及其用途
TWI822815B (zh) * 2018-07-14 2023-11-21 財團法人生物技術開發中心 抗-人類ｐｄ-ｌ１之抗體及其用途
WO2020041404A1 (fr) * 2018-08-23 2020-02-27 Macrogenics, Inc. Molécules se liant à pd-l1 et leur utilisation pour le traitement de maladies
MX2021005594A (es) 2018-11-13 2021-10-22 Compass Therapeutics Llc Constructos multiespecificos de union contra moleculas de puntos de control y usos de los mismos.
PT3880186T (pt) 2018-11-14 2024-05-28 Regeneron Pharma Administração intralesional de inibidores de pd-1 para o tratamento do cancro de pele
CN113164599B (zh) * 2018-12-24 2023-08-01 正大天晴药业集团股份有限公司 抗pd-l1单克隆抗体治疗癌症的用途
EP3902563A4 (fr) * 2018-12-27 2022-12-28 Gigagen, Inc. Protéines de liaison anti-pd-l1 et méthodes d'utilisation de celles-ci
WO2020151759A1 (fr) 2019-01-25 2020-07-30 正大天晴药业集团股份有限公司 Composition pharmaceutique combinée pour le traitement de tumeurs
WO2020156500A1 (fr) * 2019-01-31 2020-08-06 正大天晴药业集团股份有限公司 Utilisation d'un anticorps anti-pd-l1 dans le traitement du cancer de la tête et du cou
MA55084A (fr) 2019-02-28 2022-01-05 Regeneron Pharma Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau
KR20210136071A (ko) 2019-03-06 2021-11-16 리제너론 파아마슈티컬스, 인크. 암을 치료하는데 있어서 증진된 효능을 위한 il-4/il-13 경로 억제제
AU2020242144A1 (en) 2019-03-15 2021-11-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Combined pharmaceutical composition for treating small cell lung cancer
CN111973739B (zh) * 2019-05-23 2024-02-13 正大天晴药业集团股份有限公司 抗pd-l1单克隆抗体治疗癌症的用途
WO2020239085A1 (fr) * 2019-05-30 2020-12-03 正大天晴药业集团南京顺欣制药有限公司 Composition pharmaceutique combinée pour le traitement du mélanome
CN113905761A (zh) * 2019-06-10 2022-01-07 正大天晴药业集团南京顺欣制药有限公司 治疗驱动基因阳性肺癌的联用药物组合物
CN112168961A (zh) * 2019-07-03 2021-01-05 正大天晴药业集团南京顺欣制药有限公司 治疗结直肠癌的联用药物组合物
WO2021024020A1 (fr) 2019-08-06 2021-02-11 Astellas Pharma Inc. Polythérapie impliquant des anticorps dirigés contre la claudine 18.2 et inhibiteurs de point de contrôle immunitaire pour le traitement du cancer
WO2021037184A1 (fr) 2019-08-30 2021-03-04 正大天晴药业集团南京顺欣制药有限公司 PROTÉINE DE FUSION CIBLANT PD-L1 ET TGF-β ET SON UTILISATION.
WO2021063352A1 (fr) * 2019-09-30 2021-04-08 和铂医药(上海)有限责任公司 Protéine de liaison à l'antigène anti-pd-l1 et son application
EP4056592A4 (fr) * 2019-11-08 2024-03-20 Jiangsu Simcere Pharmaceutical Co., Ltd. Anticorps dirigé contre le ligand 1 de la mort cellulaire programmée humain (pd-l1) et son utilisation
WO2021167885A1 (fr) * 2020-02-21 2021-08-26 Macrogenics, Inc. Molécules de liaison à cd137 et leurs utilisations
KR20220163991A (ko) 2020-04-02 2022-12-12 치아타이 티안큉 파마수티컬 그룹 주식회사 Cd47에 결합하는 항원-결합 폴리펩타이드 및 이의 용도
EP4144371A4 (fr) 2020-04-30 2024-05-22 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Médicament combiné pour le traitement du cancer du rein
KR20230015954A (ko) 2020-05-26 2023-01-31 리제너론 파마슈티칼스 인코포레이티드 Pd-1 억제제의 투여에 의한 자궁경부암의 치료 방법
US20230263795A1 (en) 2020-06-02 2023-08-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Combined pharmaceutical composition of c-met kinase inhibitor and anti-pd-l1 antibody
CN115698076A (zh) 2020-06-30 2023-02-03 正大天晴药业集团股份有限公司 用于治疗肿瘤的药物
JP2023532768A (ja) 2020-07-07 2023-07-31 バイオエヌテック エスエー Ｈｐｖ陽性癌の治療用ｒｎａ
EP4197554A1 (fr) 2020-08-13 2023-06-21 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Médicament combiné pour le traitement d'un sarcome des tissus mous
JP2023540217A (ja) 2020-08-26 2023-09-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｐｄ－１阻害剤を投与することによりがんを処置する方法
CN116194142A (zh) 2020-09-03 2023-05-30 瑞泽恩制药公司 通过施用pd-1抑制剂治疗癌症疼痛的方法
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (fr) 2020-12-21 2022-06-30 BioNTech SE Programme de traitement faisant intervenir des protéines cytokines
WO2022135667A1 (fr) 2020-12-21 2022-06-30 BioNTech SE Arn thérapeutique pour le traitement du cancer
KR20230141817A (ko) 2021-02-07 2023-10-10 치아타이 티안큉 파마수티컬 그룹 주식회사 이중특이 항체
JP2024511106A (ja) 2021-03-23 2024-03-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｐｄ－１阻害剤を投与することにより免疫抑制または免疫不全患者におけるがんを処置する方法
TW202304506A (zh) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
CN117083083A (zh) 2021-03-29 2023-11-17 正大天晴药业集团股份有限公司 Toll样受体7激动剂和抗PD-L1抗体的药物联合
TW202313682A (zh) 2021-05-18 2023-04-01 英商凱麥博有限公司 抗icos抗體之用途
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
EP4370552A1 (fr) 2021-07-13 2024-05-22 BioNTech SE Agents de liaison multispécifiques contre cd40 et cd137 en polythérapie du cancer
EP4373505A1 (fr) 2021-07-19 2024-05-29 Regeneron Pharmaceuticals, Inc. Combinaison d'inhibiteurs de point de contrôle et d'un virus oncolytique pour le traitement du cancer
CN117597146A (zh) 2021-07-22 2024-02-23 正大天晴药业集团股份有限公司 用于治疗胃癌和/或食管胃结合部癌的联用药物
CN115521378B (zh) * 2021-07-23 2023-12-22 南京吉盛澳玛生物医药有限公司 Pd-l1抗体及其用途
CN116209443A (zh) 2021-08-05 2023-06-02 正大天晴药业集团股份有限公司 治疗小细胞肺癌的药物组合
CN117642181A (zh) * 2021-09-06 2024-03-01 正大天晴药业集团股份有限公司 用于治疗食管癌的药物组合
KR20240056587A (ko) 2021-09-16 2024-04-30 치아타이 티안큉 파마수티컬 그룹 주식회사 항-her3 항체 약물 접합체, 이의 조성물, 및 이의 용도
WO2023051674A1 (fr) 2021-09-30 2023-04-06 正大天晴药业集团南京顺欣制药有限公司 Anticorps anti-cd47 pour le traitement combiné d'une tumeur du sang
WO2023051926A1 (fr) 2021-09-30 2023-04-06 BioNTech SE Traitement impliquant un arn non immunogène pour vaccination antigénique et antagonistes liant l'axe pd-1
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023083439A1 (fr) 2021-11-09 2023-05-19 BioNTech SE Agoniste de tlr7 et combinaisons pour le traitement du cancer
CN118201963A (zh) 2021-12-01 2024-06-14 正大天晴药业集团股份有限公司 用于治疗非小细胞肺癌的药物组合
WO2023159102A1 (fr) 2022-02-17 2023-08-24 Regeneron Pharmaceuticals, Inc. Association d'inhibiteurs de point de contrôle et de virus oncolytique pour le traitement du cancer
WO2023174408A1 (fr) * 2022-03-18 2023-09-21 正大天晴药业集团南京顺欣制药有限公司 Combinaison pharmaceutique d'anticorps anti-tim-3 et d'anticorps anti-pd-l1
WO2023222854A1 (fr) 2022-05-18 2023-11-23 Kymab Limited Utilisations d'anticorps anti-icos
WO2023232100A1 (fr) * 2022-06-02 2023-12-07 正大天晴药业集团股份有限公司 Combinaison pharmaceutique pour le traitement d'une tumeur utérine maligne
WO2024115725A1 (fr) 2022-12-01 2024-06-06 BioNTech SE Anticorps multispécifique contre cd40 et cd137 en polythérapie avec un anticorps anti-pd1 et une chimiothérapie
WO2024126457A1 (fr) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Polythérapie impliquant des agents de liaison bispécifiques se liant à cldn18.2 et cd3 et des inhibiteurs de point de contrôle immunitaire

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5994514A (en) 1991-08-14 1999-11-30 Genentech, Inc. Immunoglobulin variants
CA2118508A1 (fr) 1992-04-24 1993-11-11 Elizabeth S. Ward Production par recombinaison genetique de domaines semblables aux immunoglobulines dans les cellules procaryotes
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
JPH07291996A (ja) 1994-03-01 1995-11-07 Yuu Honshiyo ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
NZ517122A (en) 1999-08-23 2004-02-27 Dana Farber Cancer Inst Inc Novel B7-4 molecules and uses therefor
HUP0300919A2 (hu) 2000-03-24 2003-07-28 Micromet Ag Többfunkciós polipeptidek NKG2D receptor komplex epitóp kötőhellyel
CA2399940A1 (fr) 2000-04-13 2001-10-25 The Rockefeller University Amelioration des reponses immunitaires associees aux anticorps
KR20030066657A (ko) 2000-11-15 2003-08-09 오노 야꾸힝 고교 가부시키가이샤 Ｐｄ-1 결손 마우스 및 그 용도
EP1355919B1 (fr) 2000-12-12 2010-11-24 MedImmune, LLC Molecules a demi-vies longues, compositions et utilisations de celles-ci
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2002068414A2 (fr) 2001-02-27 2002-09-06 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Analogues de thalidomide utilises comme inhibiteurs potentiels de l'angiogenese
KR20090010127A (ko) 2001-03-07 2009-01-28 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을 위한 발현 기술
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
JP4409430B2 (ja) 2002-07-03 2010-02-03 小野薬品工業株式会社 免疫賦活組成物
AU2003287345A1 (en) 2002-10-31 2004-06-07 Genentech, Inc. Methods and compositions for increasing antibody production
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
CA2536408A1 (fr) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Anticorps ameliores possedant une fonction d'effecteur modifiee et procedes de fabrication associes
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
WO2005077981A2 (fr) 2003-12-22 2005-08-25 Xencor, Inc. Polypeptides fc a nouveaux sites de liaison de ligands fc
GB0400440D0 (en) 2004-01-09 2004-02-11 Isis Innovation Receptor modulators
JP4958555B2 (ja) 2004-09-22 2012-06-20 協和発酵キリン株式会社 安定化されたヒトＩｇＧ４抗体
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
CN1296385C (zh) 2005-03-30 2007-01-24 王哲 抗猪生长激素单克隆抗体及制备方法及应用
PL2439273T3 (pl) 2005-05-09 2019-08-30 Ono Pharmaceutical Co., Ltd. Ludzkie przeciwciała monoklonalne przeciwko białku programowanej śmierci komórki 1(pd-1) oraz metody leczenia nowotworów z wykorzystaniem przeciwciał anty-pd-1 samodzielnie lub w połączeniu z innymi immunoterapeutykami
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
CN102898519B (zh) * 2005-11-30 2015-10-28 Abbvie公司 抗淀粉样β蛋白的单克隆抗体及其用途
RU2008127486A (ru) 2005-12-08 2010-01-20 Милленниум Фармасьютикалз, Инк. (Us) Бициклические соединения с ингибиторной активностью в отношении киназы
EP2325209A3 (fr) 2006-03-23 2011-08-03 BioArtic Neuroscience AB Anticorps améliorés sélectifs de protofibrilles et leur utilisation
WO2007136573A2 (fr) 2006-05-15 2007-11-29 Merck & Co., Inc. Composés bicycliques antidiabétiques
EA200970108A1 (ru) 2006-07-10 2009-12-30 Байоджен Айдек Ма Инк. Композиции и способы для ингибирования роста smad4-дефицитных форм рака
CN101104640A (zh) 2006-07-10 2008-01-16 苏州大学 抗人pd-l1单克隆抗体制备及应用
US20080227704A1 (en) 2006-12-21 2008-09-18 Kamens Joanne S CXCL13 binding proteins
CA3045637A1 (fr) 2006-12-27 2008-07-10 Emory University Compositions et procedes pour le traitement d'infections et de tumeurs
CA2688275A1 (fr) 2007-05-31 2008-12-04 Genmab A/S Anticorps igg4 stables
US7615883B2 (en) 2007-06-06 2009-11-10 Meheen H Joe Wind driven venturi turbine
CA2691357C (fr) 2007-06-18 2014-09-23 N.V. Organon Anticorps diriges contre le recepteur humain de mort programmee pd-1
AU2014201367B2 (en) 2007-06-18 2016-01-28 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
US9243052B2 (en) 2007-08-17 2016-01-26 Daniel Olive Method for treating and diagnosing hematologic malignancies
MX2010003720A (es) * 2007-10-08 2010-10-20 Intrexon Corp Celulas dendriticas creadas por ingenieria genetica y usos para el tratamiento de cancer.
CN104031150A (zh) 2007-10-16 2014-09-10 Sbi生物技术有限公司 抗bst2抗体
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009114335A2 (fr) 2008-03-12 2009-09-17 Merck & Co., Inc. Protéines de liaison avec pd-1
EP2324055A2 (fr) 2008-08-25 2011-05-25 Amplimmune, Inc. Polypeptides cibles co-stimulateurs et methodes pour le traitement du cancer
EP2342228B1 (fr) 2008-09-12 2017-09-06 Oxford University Innovation Limited Anticorps spécifiques de pd-1 et leurs utilisations
US8927697B2 (en) 2008-09-12 2015-01-06 Isis Innovation Limited PD-1 specific antibodies and uses thereof
AU2013204861B2 (en) * 2008-09-26 2016-05-12 Dana-Farber Cancer Institute, Inc. Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
CA2998281C (fr) 2008-09-26 2022-08-16 Dana-Farber Cancer Institute, Inc. Anticorps anti-pd-1 humains et leurs utilisations
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
CN102282265B (zh) 2008-11-28 2020-07-24 埃默里大学 用于治疗传染病和肿瘤的方法
EP4169951A1 (fr) * 2008-12-09 2023-04-26 F. Hoffmann-La Roche AG Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
US20100197924A1 (en) 2008-12-22 2010-08-05 Millennium Pharmaceuticals, Inc. Preparation of aminotetralin compounds
JP5844159B2 (ja) * 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
HUE029619T4 (en) * 2009-03-10 2017-07-28 Biogen Ma Inc Anti-bcma antibodies
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011056644A2 (fr) 2009-10-28 2011-05-12 Centocor Ortho Biotech Inc. Anticorps anti-glp-1r et leurs utilisations
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
SI2536745T1 (sl) 2010-02-19 2016-10-28 Xencor Inc. Novi imunoadhezini CTLA4-Ig
US8993731B2 (en) 2010-03-11 2015-03-31 Ucb Biopharma Sprl PD-1 antibody
WO2011120134A1 (fr) 2010-03-29 2011-10-06 Zymeworks, Inc. Anticorps présentant une fonction effectrice améliorée ou supprimée
WO2012009705A1 (fr) 2010-07-15 2012-01-19 Zyngenia, Inc. Complexes liant ang-2 et leurs utilisations
PT2691417T (pt) 2011-03-29 2018-10-31 Roche Glycart Ag Variantes de fc de anticorpos
KR102289394B1 (ko) 2011-03-31 2021-08-13 머크 샤프 앤드 돔 코포레이션 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료
WO2012145493A1 (fr) 2011-04-20 2012-10-26 Amplimmune, Inc. Anticorps et autres molécules qui se lient à b7-h1 et à pd-1
JP2014514337A (ja) 2011-05-02 2014-06-19 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド 多発性骨髄腫治療
DK2718322T3 (en) 2011-06-06 2018-12-03 Novo Nordisk As THERAPEUTIC ANTIBODIES
TWI496886B (zh) * 2011-06-24 2015-08-21 Taipei Veteran General Hospital 提升感染性與惡性疾病之治療之免疫反應
KR20190133790A (ko) 2011-08-01 2019-12-03 제넨테크, 인크. Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법
SG11201402603WA (en) * 2011-11-28 2014-06-27 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
EP2813568A4 (fr) 2012-02-09 2016-04-06 Chugai Pharmaceutical Co Ltd Région fc modifiée d'un anticorps
EP2844289B1 (fr) 2012-04-30 2019-07-17 MedImmune, LLC Molécules ayant une fonction effectrice réduite et des demi-vies allongées, compositions et utilisations de celles-ci
CA2873402C (fr) 2012-05-15 2023-10-24 Bristol-Myers Squibb Company Immunotherapie anticancereuse par rupture de la signalisation pd-1/pd-l1
WO2013181634A2 (fr) 2012-05-31 2013-12-05 Sorrento Therapeutics Inc. Protéines liant un antigène qui lient pd-l1
CA2874144C (fr) * 2012-05-31 2023-12-19 Genentech, Inc. Procedes de traitement du cancer au moyen d'antagonistes liant l'axe pd-1 et d'antagonistes de vegf
JP2015526409A (ja) 2012-07-03 2015-09-10 ヤンセン・サイエンシズ・アイルランド・ユーシー Ｃ−末端及び中心エピトープａ−ベータ抗体
US9845356B2 (en) 2012-08-03 2017-12-19 Dana-Farber Cancer Institute, Inc. Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use
MX370848B (es) * 2012-10-04 2020-01-08 Dana Farber Cancer Inst Inc Anticuerpos monoclonales humanos anti-pd-l1 y métodos de uso.
US10034939B2 (en) 2012-10-26 2018-07-31 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
WO2014100490A1 (fr) 2012-12-19 2014-06-26 Adimab, Llc Analogues d'anticorps multivalents, et leurs procédés de préparation et d'utilisation
AR093984A1 (es) * 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
MY178882A (en) 2013-02-20 2020-10-21 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences
US9637535B2 (en) 2013-03-15 2017-05-02 Regeneron Pharmaceuticals, Inc. IL-33 antagonists and uses thereof
CN105683217B (zh) 2013-05-31 2019-12-10 索伦托治疗有限公司 与pd-1结合的抗原结合蛋白
JP6623353B2 (ja) 2013-09-13 2019-12-25 ベイジーン スウィッツァーランド ゲーエムベーハー 抗ｐｄ−１抗体並びにその治療及び診断のための使用
KR102130600B1 (ko) 2014-07-03 2020-07-08 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
SG10201900571YA (en) 2014-07-22 2019-02-27 Cb Therapeutics Inc Anti-pd-1 antibodies
CA2956399A1 (fr) 2014-08-05 2016-02-11 Cb Therapeutics, Inc. Anticorps anti-pd-l1
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
CN108368170B (zh) 2015-07-13 2022-04-15 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
WO2017024465A1 (fr) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Anticorps anti-pd-1

Also Published As

Publication number Publication date
IL250415B (en) 2020-09-30
US11827707B2 (en) 2023-11-28
EP3177649A1 (fr) 2017-06-14
SG11201700687TA (en) 2017-02-27
US10435470B2 (en) 2019-10-08
CN110964109A (zh) 2020-04-07
MX2022002364A (es) 2022-04-06
AU2021203593B2 (en) 2024-04-18
JP7144477B2 (ja) 2022-09-29
RU2017106804A (ru) 2018-09-06
ZA201700785B (en) 2021-07-28
KR102476226B1 (ko) 2022-12-12
US20170204184A1 (en) 2017-07-20
CN110964108B (zh) 2023-07-07
CA2956399A1 (fr) 2016-02-11
RU2017106804A3 (fr) 2019-08-27
MX2017001597A (es) 2017-11-17
US11111300B2 (en) 2021-09-07
EP3177649B1 (fr) 2024-02-28
CN107001463B (zh) 2020-01-17
JP2020141672A (ja) 2020-09-10
JP2017523786A (ja) 2017-08-24
IL250415A0 (en) 2017-03-30
JP6909153B2 (ja) 2021-07-28
US20200031935A1 (en) 2020-01-30
AU2015301126A1 (en) 2017-02-23
NZ766660A (en) 2024-02-23
AU2015301126B2 (en) 2021-03-11
AU2021203593A1 (en) 2021-07-01
CN110964108A (zh) 2020-04-07
BR112017002234A2 (pt) 2018-07-24
US20210371531A1 (en) 2021-12-02
CN107001463A (zh) 2017-08-01
KR20170039706A (ko) 2017-04-11
NZ728749A (en) 2023-06-30
CN110964109B (zh) 2023-08-25
WO2016022630A1 (fr) 2016-02-11
EP3177649A4 (fr) 2018-04-25
RU2722212C2 (ru) 2020-05-28
RU2722212C9 (ru) 2020-07-23

Similar Documents

Publication Publication Date Title
MX2022002364A (es) Anticuerpos anti-pd-l1.
NZ728688A (en) Anti-pd-1 antibodies
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
PH12016501894B1 (en) Anti-ox40 antibodies and methods of use
EP4249515A3 (fr) Anticorps anti-cd3 humanisés ou chimériques
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
MX2017000419A (es) Anticuerpos anti-pd-l1 y sus usos de diagnóstico.
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
EP3294766C0 (fr) Anticorps humanisé ou fragment de celui-ci spécifique pour cd3
PH12016501366A1 (en) Novel anti-baff antibodies
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
NZ761537A (en) Anti-human ox40l antibodies, uses & methods
PH12016500940A1 (en) HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
IL269645A (en) Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of using them
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
MX2023006786A (es) Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control.
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
MX2018009218A (es) Anticuerpos de cgrp y sus usos.
MX2019002349A (es) Anticuerpos inmunomoduladores biespecíficos que se fijan a receptores coestimuladores y de puntos de control.